glp 1 and cancer risk Long-term in users of GLP-1 agonists in Denmark: a nationwide emulated trial Frontiers | Reassessing cancer risk

Curr Atheroscler Rep

In October 1996, Eng licensed his patent to Amylin

Evidence level: Unsupported by the cited record Sources: Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice., Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction., ClinicalTrials.gov exact-name search, accessed 2026-07-12 How to read this: Direct efficacy findings come from obese mice, not human trials

A small retrospective study in Japan reported that dulaglutide 0.75 mg improved liver enzymes, glucose metabolism, and liver stiffness in patients with MASLD and T2DM after 12 weeks